Liver transplantation (LT) is the standard of care for both end-stage liver failure and hepatocellular carcinoma (HCC). Side effects of the main used immunosuppressive drugs have a noteworthy impact on the long-term outcome of LT recipients. Consequently, to achieve a balance between optimal immunosuppression and minimal side effects is a cornerstone of the post-LT period. Today, there are no validated markers for overimmunosuppression and underimmunosuppression, only a few drugs have therapeutic drug monitoring, and immunosuppression regimens vary from center to center and from country to country. Currently, there are many drugs with different efficacy and safety profiles. Using different agents permits a decrease in the dosage and minimizes the toxicities. A small subset of recipients achieves immunotolerance with the chance to stop immunosuppressive therapy. This article focuses on the side effects of immunosuppressive drugs, which significantly impact long-term outcomes for LT recipients. The primary aim is to highlight the balance between achieving effective immunosuppression and minimizing adverse effects, emphasizing the role of personalized therapeutic strategies. Moreover, this review evaluates the mechanisms of action and specific complications associated with immunosuppressive agents. Finally, special attention is given to strategies for reducing immunosuppressive burdens, improving patient quality of life, and identifying immunotolerant individuals.

Side Effects of Immunosuppressant Drugs After Liver Transplant / Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 18:3(2025), pp. 1-30. [10.3390/ph18030342]

Side Effects of Immunosuppressant Drugs After Liver Transplant

Gabrielli F.
Writing – Original Draft Preparation
;
Bernasconi E.
Writing – Original Draft Preparation
;
Andreone P.
Writing – Review & Editing
;
2025

Abstract

Liver transplantation (LT) is the standard of care for both end-stage liver failure and hepatocellular carcinoma (HCC). Side effects of the main used immunosuppressive drugs have a noteworthy impact on the long-term outcome of LT recipients. Consequently, to achieve a balance between optimal immunosuppression and minimal side effects is a cornerstone of the post-LT period. Today, there are no validated markers for overimmunosuppression and underimmunosuppression, only a few drugs have therapeutic drug monitoring, and immunosuppression regimens vary from center to center and from country to country. Currently, there are many drugs with different efficacy and safety profiles. Using different agents permits a decrease in the dosage and minimizes the toxicities. A small subset of recipients achieves immunotolerance with the chance to stop immunosuppressive therapy. This article focuses on the side effects of immunosuppressive drugs, which significantly impact long-term outcomes for LT recipients. The primary aim is to highlight the balance between achieving effective immunosuppression and minimizing adverse effects, emphasizing the role of personalized therapeutic strategies. Moreover, this review evaluates the mechanisms of action and specific complications associated with immunosuppressive agents. Finally, special attention is given to strategies for reducing immunosuppressive burdens, improving patient quality of life, and identifying immunotolerant individuals.
2025
18
3
1
30
Side Effects of Immunosuppressant Drugs After Liver Transplant / Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 18:3(2025), pp. 1-30. [10.3390/ph18030342]
Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.
File in questo prodotto:
File Dimensione Formato  
pharmaceuticals-18-00342-v2.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Licenza: [IR] creative-commons
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1377889
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact